Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of
chronic liver disease, and its prevalence is rising worldwide. The occurrence of non …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western
world, with a prevalence of 20%. In a subgroup of patients, inflammation, ballooning …

Non-alcoholic fatty liver disease (NAFLD) is the most common diffuse liver disease, with a
worldwide prevalence of 20% to 46%. NAFLD can be subdivided into simple steatosis and …

Background Despite the extensive scientific evidence accumulating on the epidemiological
risk factors for non-alcoholic fatty liver disease (NAFLD), evidence exploring sex-and age …

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis (>
5% of hepatocytes by histology or> 5.6% by nuclear magnetic resonance techniques) in the …

STUDY QUESTION What are the most relevant factors associated with non-alcoholic fatty
liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS)? SUMMARY …

Abstract Background Non-invasive tests (NITs) are useful to assess advanced fibrosis (AF)
in nonalcoholic fatty liver disease (NAFLD). Data from Asian countries suggest that these …

Nonalcoholic fatty liver disease (NAFLD) is a progressive metabolic liver disease with an
unknown pathogenesis and no FDA-approved drug treatment to date. Hypothyroidism has …

Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as
nonalcoholic fatty liver disease, is the most prevalent liver disorder worldwide. Historically …